Published in BMC Infect Dis on October 28, 2015
Tuberculosis Biomarkers: From Diagnosis to Protection. Infect Dis Rep (2016) 0.80
Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy. Clin Vaccine Immunol (2016) 0.79
Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy. Clin Exp Immunol (2016) 0.78
The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy. Infect Dis Poverty (2017) 0.76
The involvement of endothelial mediators in leprosy. Mem Inst Oswaldo Cruz (2016) 0.75
Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy. JCI Insight (2016) 0.75
Impact of a Reference Center on Leprosy Control under a Decentralized Public Health Care Policy in Brazil. PLoS Negl Trop Dis (2016) 0.75
Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR). PLoS Negl Trop Dis (2017) 0.75
Quantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy. Sci Rep (2016) 0.75
Autophagy Is an Innate Mechanism Associated with Leprosy Polarization. PLoS Pathog (2017) 0.75
Genetic polymorphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosy. PLoS Negl Trop Dis (2017) 0.75
Opening a Can of Worms: Leprosy Reactions and Complicit Soil-Transmitted Helminths. EBioMedicine (2017) 0.75
Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis (1966) 22.28
Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 8.85
Leprosy. Lancet (2004) 5.37
Cytokine patterns of immunologically mediated tissue damage. J Immunol (1992) 2.72
Role of contact tracing and prevention strategies in the interruption of leprosy transmission. Lepr Rev (2014) 2.68
Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol (2005) 2.50
Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 2.34
Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol (1993) 2.00
Leprosy type 1 (reversal) reactions and their management. Lepr Rev (2008) 1.81
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75
Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A (1988) 1.62
Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec (2013) 1.56
Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis (2008) 1.56
Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe (2009) 1.55
New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol (2012) 1.40
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) (2011) 1.34
Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis (2006) 1.16
Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Immunology (1998) 1.14
Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis (2011) 1.11
Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection. Clin Vaccine Immunol (2008) 1.08
Learning from leprosy: insight into the human innate immune response. Adv Immunol (2010) 1.08
Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz (2012) 1.08
Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis (2015) 1.08
Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. Clin Biochem (2011) 1.08
High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol (2002) 1.08
Nerve damage in leprosy: a continuing challenge to scientists, clinicians and service providers. Int Health (2012) 1.06
New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol (2012) 1.02
Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol (2013) 1.02
Crohn's disease susceptibility genes are associated with leprosy in the Vietnamese population. J Infect Dis (2012) 1.02
Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun (2004) 1.02
Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol (2008) 0.99
Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis (2008) 0.98
The study of Mycobacterium leprae infection in interferon-gamma gene--disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J Infect Dis (2002) 0.96
Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol (2011) 0.96
The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology (2012) 0.92
Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. PLoS Negl Trop Dis (2014) 0.92
Mycobacterium tuberculosis induces CCL18 expression in human macrophages. Scand J Immunol (2008) 0.91
Genetic variations and interactions in anti-inflammatory cytokine pathway genes in the outcome of leprosy: a study conducted on a MassARRAY platform. J Infect Dis (2011) 0.90
Insights from animal models on the immunogenetics of leprosy: a review. Mem Inst Oswaldo Cruz (2012) 0.89
Risk factors for type 1 reactions in leprosy. Int J Lepr Other Mycobact Dis (1997) 0.87
Diagnosis and treatment of leprosy reactions in integrated services--the patients' perspective in Nepal. PLoS Negl Trop Dis (2013) 0.87
Pathogen-specific epitopes as epidemiological tools for defining the magnitude of Mycobacterium leprae transmission in areas endemic for leprosy. PLoS Negl Trop Dis (2012) 0.86
Biomarkers for leprosy: would you prefer T (cells)? Lepr Rev (2013) 0.85
Incidence of Hansen's Disease--United States, 1994-2011. MMWR Morb Mortal Wkly Rep (2014) 0.84
Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. Mem Inst Oswaldo Cruz (2012) 0.83
Differential dermal expression of CCL17 and CCL18 in tuberculoid and lepromatous leprosy. PLoS Negl Trop Dis (2014) 0.81
New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis (2013) 0.80
Psoriasis and leprosy are teaching us T-cell plasticity. J Drugs Dermatol (2013) 0.80
IL-10 and NOS2 modulate antigen-specific reactivity and nerve infiltration by T cells in experimental leprosy. PLoS Negl Trop Dis (2014) 0.80
Peptides Derived from Mycobacterium leprae ML1601c Discriminate between Leprosy Patients and Healthy Endemic Controls. J Trop Med (2012) 0.80
Borderline lepromatous leprosy in an Italian man. Am J Trop Med Hyg (2013) 0.77
Persister studies in leprosy patients after multi-drug treatment. Int J Lepr Other Mycobact Dis (2005) 0.76
Efficacy of artemether-lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia. Malar J (2015) 0.95
Microscopic and molecular evidence of the presence of asymptomatic Plasmodium falciparum and Plasmodium vivax infections in an area with low, seasonal and unstable malaria transmission in Ethiopia. BMC Infect Dis (2015) 0.91
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J (2015) 0.79
Polymorphisms in chloroquine resistance-associated genes in Plasmodium vivax in Ethiopia. Malar J (2015) 0.78
Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania. Malar J (2015) 0.77